JP2022519273A5 - - Google Patents

Info

Publication number
JP2022519273A5
JP2022519273A5 JP2021545378A JP2021545378A JP2022519273A5 JP 2022519273 A5 JP2022519273 A5 JP 2022519273A5 JP 2021545378 A JP2021545378 A JP 2021545378A JP 2021545378 A JP2021545378 A JP 2021545378A JP 2022519273 A5 JP2022519273 A5 JP 2022519273A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
cancer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021545378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519273A (ja
JP7754715B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/016381 external-priority patent/WO2020163225A1/en
Publication of JP2022519273A publication Critical patent/JP2022519273A/ja
Publication of JP2022519273A5 publication Critical patent/JP2022519273A5/ja
Priority to JP2025021046A priority Critical patent/JP2025072613A/ja
Application granted granted Critical
Publication of JP7754715B2 publication Critical patent/JP7754715B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021545378A 2019-02-05 2020-02-03 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート Active JP7754715B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025021046A JP2025072613A (ja) 2019-02-05 2025-02-12 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962801590P 2019-02-05 2019-02-05
US62/801,590 2019-02-05
US201962824923P 2019-03-27 2019-03-27
US62/824,923 2019-03-27
US201962879660P 2019-07-29 2019-07-29
US62/879,660 2019-07-29
US201962882016P 2019-08-02 2019-08-02
US62/882,016 2019-08-02
US201962934424P 2019-11-12 2019-11-12
US62/934,424 2019-11-12
PCT/US2020/016381 WO2020163225A1 (en) 2019-02-05 2020-02-03 Anti-cd228 antibodies and antibody-drug conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025021046A Division JP2025072613A (ja) 2019-02-05 2025-02-12 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2022519273A JP2022519273A (ja) 2022-03-22
JP2022519273A5 true JP2022519273A5 (https=) 2023-02-13
JP7754715B2 JP7754715B2 (ja) 2025-10-15

Family

ID=69740807

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021545378A Active JP7754715B2 (ja) 2019-02-05 2020-02-03 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート
JP2025021046A Withdrawn JP2025072613A (ja) 2019-02-05 2025-02-12 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025021046A Withdrawn JP2025072613A (ja) 2019-02-05 2025-02-12 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート

Country Status (12)

Country Link
US (3) US11617798B2 (https=)
EP (1) EP3920968A1 (https=)
JP (2) JP7754715B2 (https=)
KR (1) KR20210125511A (https=)
CN (1) CN113710271B (https=)
AU (1) AU2020219732A1 (https=)
BR (1) BR112021015477A2 (https=)
IL (1) IL284974A (https=)
MX (1) MX2021009138A (https=)
SG (1) SG11202107551WA (https=)
TW (1) TWI872044B (https=)
WO (1) WO2020163225A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021251875A1 (en) 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers
WO2022098972A1 (en) 2020-11-08 2022-05-12 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
AU2022283467A1 (en) 2021-05-28 2023-12-07 Seagen Inc. Anthracycline antibody conjugates
WO2023178289A2 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
EP4518905A1 (en) * 2022-05-06 2025-03-12 Seagen Inc. Immunomodulatory antibody-drug conjugates
CN119256007B (zh) * 2022-05-31 2025-10-31 山东博安生物技术股份有限公司 抗cd228抗体及其药物偶联物
JP2025532652A (ja) * 2022-09-21 2025-10-01 シージェン インコーポレイテッド Ｃｄ１３７およびｃｄ２２８に特異的な新規融合タンパク質
AU2023347922A1 (en) * 2022-09-21 2025-03-20 Seagen Inc. Antibodies that bind cd228
WO2025025731A1 (zh) * 2023-07-28 2025-02-06 山东博安生物技术股份有限公司 一种适用于免疫组化检测cd228的诊断抗体
AR134171A1 (es) 2023-10-24 2025-12-10 Seagen Inc Compuestos quimioterapéuticos y métodos de uso

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
WO1992008802A1 (en) 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
CA2108451A1 (en) 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
DK0871490T3 (da) 1995-12-22 2003-07-07 Bristol Myers Squibb Co Forgrenede hydrazonlinkere
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
JP2002510968A (ja) * 1997-05-07 2002-04-09 ブリストル−マイヤーズ スクイブ カンパニー 組換え抗体−酵素融合タンパク質
NZ513144A (en) 1999-02-05 2003-05-30 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
US20060160174A1 (en) 2002-12-02 2006-07-20 Mcdonagh Charlotte F Modified l49-sfv exhibiting increased stability and methods of use thereof
WO2004050867A1 (en) 2002-12-02 2004-06-17 Seattle Genetics, Inc. MODIFIED L49-sFv EXHIBITING INCREASED STABILITY AND METHODS OF USE THEREOF
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
DK3248613T3 (da) 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
TW201617368A (zh) * 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
DK3270965T3 (da) * 2015-03-18 2020-06-08 Seattle Genetics Inc Cd48-antistoffer og konjugater deraf
CR20190550A (es) * 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso
CN112805238A (zh) * 2018-07-03 2021-05-14 芬内克制药股份有限公司 无水硫代硫酸钠和其调配物
US20230270877A1 (en) * 2020-11-08 2023-08-31 Seagen Inc. Combination Therapy

Similar Documents

Publication Publication Date Title
JP2022519273A5 (https=)
AU2019320336B2 (en) Combination of antibody-drug conjugate and tubulin inhibitor
CN110545846A (zh) 用于光免疫疗法的治疗组合物和相关方法
KR20160138177A (ko) 항-ｅｇｆｒ 항체 및 항체 약물 접합체
JP2017534253A5 (https=)
JP2012522513A5 (https=)
EP3638306A1 (en) Antibody-drug conjugates containing anti-globo h antibodies and uses thereof
US20220313822A1 (en) Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antibody-phthalocyanine dye conjugate and anti-pd1 antibody
WO2022182483A1 (en) Methods for local and systemic treatment of cancers, tumors and tumor cells
JP2023502876A5 (https=)
JP2023505222A (ja) 免疫増強および腫瘍処置のための方法
CN109806393B (zh) 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途
JP2024519907A (ja) 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用
WO2016163433A1 (ja) 抗ｆｇｆｒ２抗体と他剤を含む組成物
WO2026021442A1 (zh) 抗体药物偶联物在制备治疗肺癌的药物中的用途
WO2026052074A1 (zh) 包含抗体偶联药物和免疫检查点抑制剂的药物组合及其应用
EA050611B1 (ru) Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина
HK40043732A (en) Combination of antibody-drug conjugate and tubulin inhibitor
WO2024213081A1 (zh) 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途
HK40130006A (zh) 通过施用抗her2抗体-药物缀合物治疗her2突变的癌
RU2025111318A (ru) АНТИ-αvβ6 АНТИТЕЛА И КОНЪЮГАТЫ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
JP2024535034A5 (https=)
JP2024540017A5 (https=)
WO2020225282A1 (fr) Adc pour un traitement concomitant ou postérieur au docétaxel